Intercept Pharmaceuticals, Inc.
Medicine obtained by combining FXR agonist and ARB
Last updated:
Abstract:
The present invention provides an NASH therapeutic agent including: an FXR agonist, preferably obeticholic acid or a pharmaceutically acceptable salt thereof; and an ARB or a pharmaceutically acceptable salt thereof.
Status:
Grant
Type:
Utility
Filling date:
27 Mar 2017
Issue date:
23 Aug 2022